|
09:00 - 10:00 |
Peripheral T-cell Receptor Repertoire as a Prognostic Biomarker and Indicator of Treatment Response in Breast Cancer
|
劉峻宇
|
黃其晟
|
701D |
|
|
09:00 - 10:00 |
Exploring Novel Precision Strategies Involving ADCs for the Treatment of Platinum-Resistant Ovarian Cancer
|
Myong Cheol Lim
|
張志隆
|
701F |
|
|
09:30 - 10:30 |
New Frontiers in Advanced Ovarian Cancer: From First-Line Standards to Recurrence and Emerging Therapies
|
Byoung-Gie Kim
|
王鵬惠
|
701E |
|
|
10:00 - 11:00 |
Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
|
陸英明
|
楊慕華
|
701D |
|
|
10:00 - 10:30 |
The Evolving Landscape of BRAF-Targeted Therapy in CRC and Melanoma
|
謝燿宇
|
饒坤銘
|
702 |
|
|
10:00 - 11:00 |
The Integration of Next Generation Sequencing and Proteomics Precision Cancer Care
|
林宗哲
|
許駿
|
701F |
|
|
10:30 - 11:00 |
Treatment Considerations in BRAF-Mutant NSCLC: New Solution and Future Directions
|
曾政森
|
賴俊良副院長 Chun-Liang Lai M.D., Ph.D.
|
702 |
|
|
11:00 - 12:00 |
Current and Future Management of HER2 mutant NSCLC
|
李純慧
|
|
701D |
|
|
11:00 - 12:00 |
台灣小野藥品工業股份有限公司 / 台灣必治妥施貴寶股份有限公司
The effective combination therapy for unresectable or metastatic UC patient
|
賴峻毅
|
蘇文彬
|
702 |
|
|
11:00 - 12:00 |
From Registry to Therapy: Taiwan epNEC Experience and the Potential of DLL3 in Treatment
|
吳宜珍
|
|
701F |
|
|
11:00 - 12:00 |
Evolving Role of Third Generation EGFR TKIs in EGFR Mutated NSCLC - Emerging Solutions
|
夏德椿秘書長 Te-Chun, Hsia. MD. PhD.
|
蔡俊明
|
701B |
|
|
11:30 - 12:30 |
Evolving Standards in metastatic EGFRm NSCLC: Real-world Insights and Implementation of TKI-Chemotherapy Combinations
|
陳崇裕
|
楊宗穎
|
702 |
|
|
12:00 - 13:00 |
|
|
|
701F |
|
|
12:00 - 12:25 |
Navigating EGFR Heterogeneity: The Clinical Versatility of Afatinib in Real-world Practice
|
鄭文建
|
|
701D |
|
|
12:00 - 13:00 |
Navigating the Post-CDK4/6i Landscape: A Biomarker-Driven Approach to HR+ mBC
|
Shaheenah Dawood
|
|
701H |
|
|
12:00 - 13:00 |
台灣小野藥品工業股份有限公司 / 台灣必治妥施貴寶股份有限公司
Just-Right Therapy: Building Durable Control in Challenging NSCLC
|
吳教恩
|
楊政達 Cheng-Ta Yang
|
701B |
|
|
12:25 - 12:50 |
Rethinking Long-term Survival: Maximizing Cumulative Benefit through Strategic Sequential Planning
|
郭明濬
|
|
701D |
|
|
12:30 - 13:30 |
From Biomarkers to First‑Line Regimens: Precision‑Guided Treatment in Advanced GI Cancers
|
陳明晃
|
|
701A |
|
|
12:30 - 12:35 |
|
周振陽
|
周振陽
|
701E |
|
|
12:35 - 13:10 |
A New Standard of Care: How Jemperli Improves Outcomes for Patients with Primary Advanced or Recurrent Endometrial Cancer
|
Bhavana Pothuri
|
周振陽
|
701E |
|
|
12:50 - 13:00 |
|
|
|
701D |
|
|
13:00 - 14:00 |
Advancing 3L+ mCRC Care: Clinical Evidence and Real-World Insights of Fruzaqla
|
梁逸歆
|
陳明晃
|
701H |
|
|
13:00 - 14:00 |
台灣小野藥品工業股份有限公司 / 台灣必治妥施貴寶股份有限公司
Turning Tumor Shrinkage into Symptom Relief: Immunotherapy in Esophageal and Gastric Cancer
|
陳明晃
|
陳立宗
|
701C |
|
|
13:10 - 13:25 |
|
周振陽
|
周振陽
|
701E |
|
|
13:25 - 13:30 |
|
周振陽
|
周振陽
|
701E |
|
|
14:00 - 15:00 |
|
|
|
701C |
|
|
15:00 - 15:05 |
|
Ida Deleskog Lindstroem
|
|
701H |
|
|
15:00 - 16:00 |
Positioning Trodelvy in the Treatment Sequence: Insights from Second-Line Real-World Evidence and First-Line data
|
郭明濬
|
|
701C |
|
|
15:05 - 15:20 |
The Value of Liquid Biopsy & Multi-Omics Across All Stages of Cancer Care: Pan-Cancer Perspectives
|
Tan Chia-Ken Aaron
|
|
701H |
|
|
15:20 - 15:25 |
|
|
|
701H |
|
|
15:25 - 15:40 |
AI-Powered Multi-Omic ctDNA for Multi-Cancer Early Detection: Scalable Cancer Screening with SPOT-MAS
|
Le Son Tran
|
|
701H |
|
|
15:40 - 15:45 |
|
|
|
701H |
|
|
15:45 - 16:00 |
Liquid Biopsy Applications in Gastrointestinal & Colorectal Cancers: Case-Based Insights on Profiling & Monitoring Current Practice & Future Directions
|
姜乃榕
|
|
701H |
|
|
16:00 - 16:05 |
|
|
|
701H |
|
|
16:05 - 16:20 |
Clinical Integration of Liquid Biopsy in Breast Cancer and Sarcoma: Current Practice & Future Directions
|
陳偉武
|
|
701H |
|
|
16:20 - 16:25 |
|
|
|
701H |
|
|
16:25 - 16:40 |
Advanced AI-Driven Biomarkers & Liquid Biopsy Integration in Precision Oncology: Asia-Pacific Insights
|
Herbert Ho Fung Loong
|
|
701H |
|
|
16:40 - 16:45 |
|
|
|
701H |
|
|
16:45 - 17:00 |
Panel Discussion & Interactive Q&A + Closing Remarks
|
陳偉武
Nguyen Duy Sinh
Ida Deleskog Lindstroem
Tan Chia-Ken Aaron
姜乃榕
Le Son Tran
|
Herbert Ho Fung Loong
|
701H |
|